Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Q3 2024 Earnings Presentation
21 slides from Cantargia Ab's earnings presentation, Nov 15, 2024
Slide 1: Interim Report January - September
Interim Report January - September Nov 15, 2024
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: News flow during/after period
News flow during/after period… Nadunolimab • MD Anderson Cancer Center received clearance from the FDA to start leukemia study funded by a grant from the US Ministry of Defence. • First results in the randomized phase 2 trial in TNBC, TRIFOUR, expected in the first half of 2025. • New results at the
Slide 4: CAN10 – Opportunity in Autoimmune/Inflammatory Disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 5: CAN10 developed to block IL-1 family with precision
CAN10 developed to block IL-1 family with precision • CAN10 prevents signaling from IL1/, IL-33 and IL36// • CAN10 binds IL1RAP with pM affinity and prevents IL1RAP interaction with the IL-1, IL- 33 and IL-36 receptors • CAN10 has shown robust efficacy in preclinical models of several diseases
Slide 6: Overview of Hidradenitis Suppurativa (HS)
Overview of Hidradenitis Suppurativa (HS) HS – a severe chronic inflammatory skin disease • HS is a diverse disease with several inflammatory components involved in the pathology • Estimated HS prevalence of 0.7-1.2% Inadequate current treatments • Antibiotics • Steroids • Anti-TNFα (Humira), anti-I
Slide 7: External clinical results strongly support CAN10 in HS
External clinical results strongly support CAN10 in Hidradenitis Suppurativa (HS) Spesolimab Spesolimab 100 10 IL-36R-blockade (spesolimab, BI) positive results on disease severity1 Draining Tunnel count Change in IHS4 5 • Efficacy in Phase 2 randomized controlled study (NCT04762277): iHS4, HASI- (%
Slide 8: CAN10 for treatment of Hidradenitis Suppurativa (HS)
CAN10 for treatment of Hidradenitis Suppurativa (HS) 8
Slide 9: CAN10 first-in-human study - SAD part
CAN10 first-in-human study - SAD part Design Results • Blinded, placebo-controlled study • No safety signals • Nine dose groups from 1 to 400 mg CAN10 incl. 2 patients on • Receptor occupancy documented (at Cmax) placebo in each group • Potent PD effects on IL-1 & IL-36 at Cmax and day 8 Receptor Oc
Slide 10: Nadunolimab (CAN04) Clinical Results
NADUNOLIMAB (CAN04) CLINICAL RESULTS
Slide 11: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT 100% IL1RAP-expressing tumors 75% 50% 25% 0% t l r al er L C t ic as ta e e C C SC re a r e re c L iv ag NS ad d N nc B lo ph H Bl Pa Co Es o
Slide 12: Pancreatic cancer – Efficacy (1st line with gem/abraxane)
Pancreatic cancer – Efficacy (1st line with gem/abraxane) OS by IL1RAP subgroup IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% → IL1RAP linked to specific KRAS mutations and worse prognosis → Significantly prolonged OS in ILRAP High vs IL1RAP Low patients (14.2
Slide 13: Nadunolimab and alleviation of neuropathy
Nadunolimab and alleviation of neuropathy CORRELATION BETWEEN NADUNOLIMAB DOSE LEVEL AND DECREASE IN NEUROPATHY SIMILAR POSITIVE EFFECTS IN COMBINATION WITH OXALIPLATIN AND POTENTIALLY ADC-S 13
Slide 14: NSCLC – Strongest effects in patients no longer responding to PD1-inhibitors
NSCLC – Strongest effects in patients no longer responding to PD1-inhibitors SUBGROUP ANALYSIS FROM 40 PATIENTS SHOW VERY STRONG DATA IN 2ND LINE NON-SQ NSCLC, A GROUP WITH HIGH MEDICAL NEED 14
Slide 15: Nadunolimab key findings
Nadunolimab key findings • More than 300 patients treated giving robust data • Very strong data in defined subgroups of patients with PDAC and NSCLC • Diagnostic tests in development • Good safety and reduction of neuropathy (abraxane, oxaliplatin) • Data being generated in additional cancers (e.g.
Slide 16: Milestones & Financing
MILESTONES & FINANCING
Slide 17: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC TNBC AML/MDS CAN10 milestones • Phase 2 or 3 clinical • Randomized Phase 2 • Start phase 1/2 Q4 • Phase 1 final data H1 • New preclinical and trial in high IL1RAP top-line data in H1 2024 (DOD sponsored 2025 translational results patients starting H2 2
Slide 18: II. Finance
II. FINANCE
Slide 19: Financial Highlights – as of September 30, 2024
Financial Highlights – as of September 30, 2024 R&D Expenses G&A & OOI/OOE Reported loss for the period SEK 38.9m SEK 3.5m SEK 42.0m Q3 (Q3 2023: SEK 75.3m) (Q3 2023: SEK 3.4m) (Q3 2023: SEK 76.5m) Reduction of ~48%, reflecting fewer clinical studies G&A at SEK 3.9m (SEK 3.3m) in the quarter, Operat
Slide 20: Cash Flow, Cash Position and the Rights Issue
Cash Flow, Cash Position and the Rights Issue MSEK Operating Cash Outflow 200 195 SEK 44.4m (September 30, 2023: SEK 85.7m) 143 120 Available funds 140 105 SEK 59.8m 108 (September 30, 2023: SEK 200.2m) 60 85 80 Rights Issue 2024 55 60 35 • The proposed rights issue, subject to approval by EGM, is e
Slide 21: Important Information
Important Information THIS PRESENTATION IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, Any securities referred to herein have not been, and will not be, registered under the US Securities Act of 1933, as amended IN OR INTO THE UNITED STATES, INCLUDING I